Ibrutinib

Ibrutinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Relapsed Hematologic Malignancy、Refractory Hematologic Malignancy、Relapsed Primary Central Nervous System Lymphoma、Refractory Primary Central Nervous System Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Ibrutinib 研究

• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  I 期 / II 期招募中美国NCT06536049

• A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  III 期招募中美国澳大利亚比利时BrazilNCT06136559

• Pembrolizumab, Ibrutinib and Rituximab in PCNSL

  I 期 / II 期招募中美国NCT04421560

• A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

  III 期招募中中国NCT07377578

• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  II 期招募中美国NCT06649812

• Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

  不适用招募中美国NCT05724121

• A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

  I 期 / II 期招募中挪威瑞典NCT04771507

• SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

  不适用招募中荷兰NCT07021495

• Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

  II 期招募中意大利NCT04908228

• Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

  II 期 / III 期招募中英国NCT04061512

• Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

  不适用招募中法国NCT06299540

• Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  II 期招募中美国NCT06757647

• Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

  I 期 / II 期招募中中国NCT04494503

• Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

  II 期招募中美国NCT04840602

• A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

  II 期招募中美国比利时德国意大利NCT07124078

• Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

  II 期招募中中国NCT06958705

• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  I 期 / II 期招募中美国NCT03223610

• Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  I 期招募中美国澳大利亚NCT03666000

• A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

  I 期招募中美国NCT07082868

• Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

  不适用招募中美国NCT05643235

• Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

  I 期 / II 期招募中BelarusNCT06762431

• A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia

  不适用招募中RomaniaNCT07602088

• CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

  II 期招募中德国NCT06482684

• A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  II 期招募中美国NCT06520098

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。